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Abstract
In acute portal vein thrombosis (APVT) unrelated to cirrhosis, antico-
agulant therapy is classically started with low molecular weight hep-
arin or vitamin K antagonists. New direct-acting oral anticoagulants 
(DOACs) are used in the treatment of venous thrombosis outside the 
splanchnic vascular bed, but not in the latter. We report a young female 
with APVT occurring in a non-cirrhotic liver linked to heterozygosity 
of factor V-Leiden and prothrombin G20210A gene mutations. Rivar-
oxaban was started, with total recanalization of the left and partial re-
canalization of the right portal vein branches, without complications. 
New DOACs do not need daily subcutaneous injections nor routinely 
blood coagulation control tests, making its use attractive, eventually 
increasing patient’s compliance. If proved to be safe and effective in 
the future studies, its use may be extended to PVT treatment. This case 
shows that rivaroxaban was safe, not only prevented the extension of 
thrombosis in the portal tract, but also resolved PVT, at least partially.
Keywords: Portal vein thrombosis; Anticoagulation; Direct-acting 
oral anticoagulants
Introduction
Portal vein thrombosis (PVT), an event that is associated with 
a large spectrum of clinical presentations and severity, may be 
related to cirrhosis, malignancy, local factors or idiopathic [1]. 
A diagnostic workup to identify an underlying pro-thrombotic 
condition must be undertaken. In acute portal vein thrombosis 
(APVT) unrelated to cirrhosis, early anticoagulant treatment 
is indicated in order to achieve recanalization and, therefore, 
avoid future complications [1]. With conventional anticoagu-
lant treatments (low molecular weight heparin (LMWH) or vi-
tamin K antagonists), recanalization occurs in up to one-third 
of patients, being more difficult to achieve when ascites or oc-
cluded splenic vein are present [2]. In contrast, if anticoagula-
tion is not started, recanalization is exceptional [1, 3]. The use 
of DOACs is being generalized [4], but they are not routinely 
used in PVT and are not yet mentioned in the latest guidelines 
as an alternative treatment [1]. Recent data, however, indicate 
that this new class of anticoagulants is increasingly used also 
in patients with splanchnic vein thrombosis [5, 6].
Case Report
A 28-year-old healthy female, active smoker of 5 pack-year 
and under oral contraceptive (ethinylestradiol and gestodene) 
presented to the emergency department with severe epigas-
tric pain of 5-day duration. No nausea, vomiting, diarrhea or 
bloody stools were reported; she was afebrile, hemodynami-
cally stable and physical examination was normal except for 
pain on the upper quadrants without signs of peritoneal irrita-
tion or ascites. Renal function and liver profile were normal; 
CBC revealed only discrete anemia (hemoglobin of 11.8 g/dL), 
with normal platelet count; D-dimers were elevated (948 ng/
mL), INR and partial thromboplastin time were within the nor-
mal range; C-reactive protein was elevated (64.18 mg/L) with 
no infection focus found. Abdominal ultrasound with Doppler 
revealed thrombosis of more than 50% of the lumen of both 
right and left portal branches with no extension to the portal 
vein trunk, superior mesenteric or splenic veins. A computed 
tomography (CT) scan confirmed those findings with normal 
liver morphology and no ascites. Upper endoscopy revealed no 
portal hypertension-related complications. The patient was ad-
mitted at the intermediate care unit and unfractionated heparin 
for 24 h was started with a subsequent relay to LMWH (enoxa-
parin) in the dose of 1 mg/kg twice daily. Two days after she 
was discharged, and after discussion and agreement with the 
Manuscript accepted for publication March 01, 2017
aServico de Cuidados Intensivos - Unidade Intermedia Medica, Centro Hospi-
talar do Porto, Hospital Sto Antonio, Porto, Portugal
bEpiUnit - Instituto de Saude Publica da Universidade do Porto, Porto, Por-
tugal
cInstituto de Ciencias Biomedicas de Abel Salazar - UP, Porto, Portugal
dServico de Hematologia - Centro Hospitalar do Porto, Hospital Sto Antonio, 
Porto, Portugal
eServico de Radiologia, Centro Hospitalar do Porto, Hospital Sto Antonio, 
Porto, Portugal
fHepatology, Inselspital, Berne, Switzerland
gCorresponding Author: Filipe Nery, Servico de Cuidados Intensivos - Uni-
dade Intermedia Medica, Centro Hospitalar do Porto, Hospital Sto Antonio, 
Largo Prof. Abel Salazar, S/N 4000-001 Porto, Portugal. 
Email: filipegaionery@gmail.com
doi: https://doi.org/10.14740/gr806w
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org142
DOACs in Acute Portal Vein Thrombosis  Gastroenterol Res. 2017;10(2):141-143
patient, she received rivaroxaban treatment 15 mg twice daily. 
By that time she was nearly asymptomatic and instructed to 
stop smoking and to substitute previous oral contraceptive for 
a progestative one. Treatment was continued for 3 weeks and 
then 20 mg daily. The 1-month CT scan control showed total 
recanalization of the left branch and persistence of right branch 
thrombosis but with partial recanalization. No extension of the 
thrombus was documented (Fig. 1). Those findings were simi-
lar in the 6-month CT scan. Pro-thrombotic workup diagnosis 
revealed negativity for JAK2 and calreticulin mutations, nor-
mal homocysteine serum levels, absence of lupus anticoagu-
lant and negativity for paroxysmal nocturnal hemoglobinuria. 
Anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin and 
anti-phosphatidylserine antibodies were all negative. Factor V-
Leiden and prothrombin G20210A gene mutations were both 
found to be positive in heterozygosity. The patient remains un-
der rivaroxaban 20 mg daily, asymptomatic with normal renal 
function and liver profile with no documented complications 
of the anticoagulant treatment.
Discussion
To our knowledge, this is the first case ever reported concern-
ing treatment with DOACs for a patient with APVT unrelated 
to cirrhosis. Three other reports using rivaroxaban to treat 
APVT were published, but all of them in patients with under-
lying chronic liver diseases [7-9]. In all, total recanalization of 
the affected segments was achieved after a 1-, 6- and 3-month 
treatment period, respectively. Rivaroxaban doses varied be-
tween 10 and 20 mg daily. More recently, another successful 
case of rivaroxaban use for a recurrent PVT in a patient with 
a Child-Pugh class A cirrhosis, with total recanalization was 
published [10]. In all described cases, none complication re-
lated to rivaroxaban use was documented. In cirrhosis, the use 
of either direct thrombin inhibitors, as dabigatran, or direct 
factor Xa inhibitors, as rivaroxaban, apixaban or endoxaban, 
may be, at least in theory, even more effective than LMWH or 
vitamin K antagonists. This because it has been postulated that 
lower portal flow velocities, which may raise the risk of PVT 
development, may lead to a lower wash out of active thrombin 
generated in portal circulation and thus contribute to a “local” 
higher prothrombotic environment [11]. Other major concern 
about DOACs use is also its safety, since they all are metabo-
lized in the liver [4].
According to current EASL recommendations, treatment 
in the setting of APVT unrelated to cirrhosis should be with 
unfractionated heparin or LMWH in therapeutic doses with a 
subsequent substitution for a vitamin K antagonist targeting 
an INR between 2 and 3 [1]. In this particular case, and un-
der rivaroxaban treatment, a rapid and total recanalization was 
achieved in left portal branch but not completely in the right, 
probably linked to a more “occlusive” thrombosis in the latter. 
Also, in our patient, rivaroxaban proved to be safe, with no 
bleeding complications reported to date. The dose of rivaroxa-
ban chosen was the one indicated for deep vein thrombosis and 
pulmonary embolism, which was higher than in almost all of 
the other case reports, but this patient did not have concomitant 
liver disease nor acute decompensation/failure. Also, rivaroxa-
ban was started 2 days after LMWH was started, as one of 
the options suggested by recommended guidelines for acute 
pulmonary embolism [12]. This may reflect a more cautions 
strategy in the acute setting of PVT, allowing the management 
of potential complications that may arise in the first hours of 
hospitalization with the medications that physicians are more 
used to.
Figure 1. Extension of PVT at diagnosis (M0), involving the totality of the right (R1) and segments of the left portal vein branches 
(L1). Evolution of PVT under rivaroxaban at the end of the first (M1) and sixth (M6) months of treatment. Total recanalization is 
seen at the left portal vein branch and partial at the right portal vein branch. 
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Two series have been published so far reporting the use 
of DOACs in patients with splanchnic vein thrombosis [5, 6]. 
The results of these two papers strongly suggest that this new 
class of anticoagulants is safe, since the incidence of major 
bleedings and other drug-induced side effects was similar as 
in patients treated with conventional anticoagulation. Since 
DOACs are increasingly used off label in this indication, more 
data about safety and efficacy are eagerly needed.
This case report suggests that the treatment of APVT in 
a patient without underlying liver disease can 1) prevent the 
extension of the thrombus in the portal tract; 2) resolve PVT, 
at least partially, and most likely when a non-occlusive throm-
bosis occurs and; 3) be safe. In this setting, randomized con-
trolled studies are needed in order to assess efficacy and safety 
of DOACs compared to LMWH or vitamin K antagonists be-
fore its generalization.
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